

Date and Time: **Monday 22nd April 2013 (10.00 – 5.00pm)**

Minutes: confirmed

Guideline Development Group Meeting 5: Dyspepsia & GORD

Place: NICE office, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BD

Present: Peter Barry (Chair) (PB)
John de Caestecker (JD)
Mark Follows (MF)
Alex Ford (AF)
Ann Harding (AH)
Janusz Jankowski (JJ)
Mimi McCord (MM)
Clodna McNulty (CM)

Apologies: Hugh Barr (HB)

In attendance:

| | | |
|---------------------|---------------------|--|
| NICE Staff: | | |
| Emma Banks (EB) | Gabriel Rogers (GR) | |
| Ben Doak (BD) | Toni Tan (TT) | |
| Katy Harrison (KH) | Rachel Houten (RH) | |
| Emma McFarlane (EM) | Michael Heath (MH) | |

Observers:

| | | |
|--------------------------|--|--|
| Tony Smith (NICE – QS) | | |
| Craig Grime (NICE – ICG) | | |

Notes

1. PB welcomed the group to the fifth meeting of this GDG. Apologies were received from HB and no new conflicts of interest were declared. Minutes for the previous meeting were agreed.
2. EM revisited the review protocol previously agreed with the GDG in order to carry out a review of the evidence for question 5i) which asks – in patients with symptoms of dyspepsia who are positive for *Helicobacter pylori*, which eradication regimens are the most clinically effective in the eradication of *H pylori*. She then went on to summarise those papers excluded and included within the evidence review as a result of the criteria.

Notes

3. EM presented the GRADE tables and data for the outcomes antibiotic resistance, adherence to medication and adverse events. The group then discussed all the information presented and evidence statements were reviewed and changes agreed.
4. KH went on to present the outcomes for eradication rates, firstly explaining the evidence was analysed using a network meta analysis which is often used when there are multiple treatments for a decision problem and particularly useful when published studies are not available comparing each treatment of interest. As a result of this approach treatments can be ranked in terms of effectiveness. The group then discussed the information presented and evidence statements were reviewed and changes agreed.
5. GR presented a summary of the health economic evidence for this question. The group discussed the uncertainty of the cost effectiveness as this was driven by the uncertainty of which regimen is most effective.
5. Following the presentation of all clinical and health economic evidence the group then drafted a number of recommendations for review question 5i).
5. KH and EM discussed and agreed with the GDG the approach to review question 5ii) – which asks what *H. pylori* eradication regimens should be offered as second-line treatments when first-line treatments fail?
6. PB closed the meeting and thanked everyone for attending.

Date and venue of the next meeting:

Next Meeting: 5 June 2013 at NICE office, City Tower, Piccadilly Plaza, Manchester, M1 4BD